TroVax + Interleukin-2
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Renal Cell
Conditions
Carcinoma, Renal Cell
Trial Timeline
Aug 1, 2004 → Jul 1, 2008
NCT ID
NCT00083941About TroVax + Interleukin-2
TroVax + Interleukin-2 is a phase 2 stage product being developed by Oxford Biomedica for Carcinoma, Renal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00083941. Target conditions include Carcinoma, Renal Cell.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00083941 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Renal Cell